CPR builds on the proprietary antibody engineering technology developed by the Chugai Group in order to achieve our goals.
ESG at Chugai Group
Chugai Group conducts its business activities to fulfill its mission of benefiting the medical community and human health around the world.
Browse through the latest news and developments by CPR and the Chugai Group.
- New Longer-Term Safety Data of Chugai’s Satralizumab in Adults and Adolescents with Neuromyelitis Optica Spectrum Disorder Presented at EAN
- Support for Control of Novel Coronavirus in Japan
- Chugai Enters into a License Agreement for Chugai’s Antibody Engineering Technologies with Eli Lilly and Company